Amgen Pays $71 Million for Promoting Off-Label Drug Uses

Pharmaceutical Giant Amgen Pays States to Settle Illegal Promotion of Off-Label Uses for Drugs Biotech and pharmaceutical company Amgen has agreed to pay 48 states a settlement amount of $71 million after a group of attorneys general claimed the company intentionally promoted off-label uses for two of its major drugs. Amgen had been accused of … [Read more...]

Pfizer Settles Kidney Transplant Drug Lawsuit for $35 Million

Pfizer Settles Off-Label Kidney Transplant Drug Lawsuit with 41 States for $35 Million A total of 41 states have settled a lawsuit against Pfizer and its subsidiary Wyeth Pharmaceuticals for off-label promotion and use of a kidney transplant drug for $35 million. The personal injury lawsuit alleged that Wyeth trained its sales staff to promote … [Read more...]

Arkansas To Ask Court to Reconsider Risperdal Penalty

Attorney General Will Ask Arkansas Court to Reconsider Overturned Risperdal Penalty On March 20th, a court in Arkansas overturned the $1.2 billion verdict against Johnson & Johnson for off-label marketing of its anti-psychotic drug, Risperdal, which was awarded in 2012. Now, Arkansas Attorney General Dustin McDaniel announced that he will ask … [Read more...]

J&J to Pay $5.9 Million Risperdal Penalty

Montana Rules J&J Subsidiaries to Pay Millions for Risperdal Marketing A subsidiary of Johnson & Johnson has agreed to pay $5.9 million after a Montana court ruled that Risperdal was marketed off-label. The settlement claims that Janssen Pharmaceuticals, Risperdal’s manufacturers, marketed Risperdal for inappropriate uses in children and … [Read more...]

J&J Begins Risperdal Fight in Arkansas

Johnson & Johnson Begins Fight Against $1.2 Billion Risperdal Judgment in Arkansas Last month, Johnson & Johnson filed appeals in various states which had ruled to penalize the pharmaceutical giant for off-label marketing of its antipsychotic drug, Risperdal. On Thursday, February 27th, the appeals process in Arkansas began, with J&J … [Read more...]

Endo Settles Lidoderm Marketing Lawsuit for $171.9 Million

Endo Pharmaceuticals Pays Settlement for Off-Label Marketing of Lidoderm Pain Patch Endo Health Solutions Inc and its subsidiary Endo Pharmaceuticals have agreed to pay $171.9 million to settle False Claims allegations for off-label marketing of their pain patch, Lidoderm. Endo Pharmaceuticals is also a subsidiary of American Medical Systems, and … [Read more...]

BestLawyers.comAVBetter Business Bureau